RAS Mutation Testing in the Circulating Blood of Patients With Metastatic Colorectal Cancer

RAS Mutation Testing in the Circulating Blood of Patients With Metastatic Colorectal Cancer: Concordance With the "Standard" Testing Method From Tumor Tissue and Review of Associated Timelines and Costs

This study will evaluate the concordance of RAS mutation detection between the results obtained from circulating tumor DNA and those obtained with the "standard" method (testing from tumor tissue).

Inclusion Criteria:

• Pathologically confirmed metachronous or synchronous metastatic colorectal cancer
• No prior chemotherapy with the exception of adjuvant chemotherapy completed ≥ 6 months prior to enrollment
• Signed written informed consent obtained prior to any study specific screening procedures
• Patients willing to provide a blood sample for Translational Research

Exclusion Criteria:

• No tumor block available
• Previous malignancy in the last 5 years
• Medical, sociological, psychological or legal conditions that would not permit the patient to sign informed consent